Full-Time

Senior Director Commercial Data Enablement & Platforms Suite Lead

Posted on 8/21/2026

Jazz Pharmaceuticals

Jazz Pharmaceuticals

1,001-5,000 employees

Biopharmaceuticals focused on neuroscience and oncology

Compensation Overview

$224k - $336k/yr

Pennsylvania, USA

Remote

Remote within Pennsylvania; 20% to 30% travel is required.

Bachelor's, Master's, MBA

Category
Data & Analytics (1)
Required Skills
Agile
Machine Learning
Data Engineering
Data Governance
Data Analysis
Snowflake

Get referred to Jazz Pharmaceuticals

See people who can refer or advise you

Requirements
  • A bachelor's degree in business, data science, analytics, technology, engineering, healthcare, or a related field is required.
  • At least 15 years of experience in data management, data platforms, data strategy, analytics, or related domains, including building and scaling enterprise data capabilities and governance frameworks in a highly regulated industry.
  • At least 5 years of experience in pharmaceuticals, with experience in data enablement, data platforms, or commercial data management.
  • At least 6 to 8 years of experience leading people, including managing and developing high-performing teams and driving accountability across functions.
  • Experience with global data platforms, data governance solutions, master data management tools, customer relationship management systems, reporting tools, or comparable technologies.
  • Strong understanding of commercial data and how it supports business needs in pharmaceutical or healthcare industries.
  • Deep understanding of commercial data operating models, including data governance, data quality management, stewardship, audit readiness, and continuous improvement within modern data ecosystems.
  • Deep understanding of commercial data management, including customer, account, payer, and patient data, and how those data are governed and integrated, including personally identifiable information and the General Data Protection Regulation.
  • Strong understanding of enterprise data platforms and architecture, including data fabric or data mesh, master data management, data integration, and semantic layers that enable scalable and compliant data access across brands and regions.
  • Strong command of data standardization and reuse frameworks, including data models, taxonomies, and metadata management that reduce duplication and enable consistent, interoperable data.
  • Familiarity with omnichannel data flows and integration across digital, field, and third-party data sources to enable unified customer views and engagement.
  • Knowledge of best practices associated with data mesh structures and data modeling, and familiarity with AWS Redshift and Snowflake.
  • Experience working within Agile product development teams and product operating models.
  • Experience with artificial intelligence, machine learning, data automation, or advanced analytics workflows, including enabling data pipelines and platforms that support predictive models, personalization, and decision intelligence.
  • Experience leading and developing a high-performing team, including resource planning, performance management, and talent development to support evolving business needs.
Responsibilities
  • Set the vision, multi-year strategy, and capability roadmaps for the Commercial Data Enablement and Platforms team, aligned to enterprise customer-experience priorities and the capability operating model.
  • Define and govern a scalable, centralized commercial data operating model covering data sourcing, ingestion, standardization, governance, and quality frameworks across brands, markets, and functions.
  • Establish and maintain commercial data standards that enable scalability, interoperability, and reuse while reducing duplication, rework, and fragmentation.
  • Align commercial data to enterprise governance frameworks, ensuring stewardship, data quality, and lifecycle management.
  • Own budget and resource allocation, making investment decisions across capabilities and teams.
  • Set and evolve the team vision and strategy, translate franchise, functional, regional, and customer strategies into priorities, and define how commercial data capabilities mature over time.
  • Partner with domain and technical domain leads on resource planning, capability development, technology roadmaps, and operating-model evolution.
  • Own and evolve the Commercial Data Enablement and Platforms Suite vision and strategy.
  • Partner with the heads of Customer Experience and Digital Enterprise Capabilities Customer Insights and Data on resource planning, talent strategy, and capability development.
  • Lead and develop team leads, including the global data strategy lead and capability owners for US, European and international data master and management, data management, HCP/HCO data management, and patient and payer data management.
  • Provide executive oversight of end-to-end data operations, including data quality monitoring, data builds, governance adherence, vendor performance, and continuous improvement of data availability and reliability.
  • Manage vendor partners and ensure accountability, quality delivery, and alignment to objectives.
  • Foster a high-performance culture of collaboration, learning, and continuous improvement.
  • Partner with Activation Leads to embed user needs, readiness, enablement, and adoption considerations into strategy and prioritization.
  • Work with franchise, functional, and regional stakeholders to define commercial data priorities while balancing local needs with global standards.
  • Connect capabilities across Customer Analytics and Insights, Advanced Analytics and Optimization, and Customer Orchestration in partnership with Technology, Legal, and Compliance.
  • Represent the Commercial Data Enablement and Platforms team in cross-functional forums, manage dependencies, resolve risks, and drive adoption of enterprise data platforms, standards, and governance practices.
  • Lead resolution of complex cross-team issues affecting campaign orchestration performance or adoption.
  • Identify organizational training needs and partner with Learning and Development to design and deliver targeted capability-building programs.
Desired Qualifications
  • An advanced degree, such as an MBA or relevant graduate degree, is preferred.
  • Experience working in the capability operating model.
  • Experience partnering with enterprise platform teams or global capability teams supporting digital and operational capabilities.
  • Experience working in rare disease or specialty brands, with understanding of their stakeholder dynamics.
  • Experience leading and developing distributed, matrixed teams, including global and onshore/offshore models, while aligning resources, driving accountability, and ensuring consistent delivery standards.

Jazz Pharmaceuticals develops and markets therapies in neuroscience and oncology. Its products include Xyrem and the lower-sodium option Xywav for narcolepsy, Epidiolex for seizures in severe epilepsy, and oncology medicines Zepzelca for small cell lung cancer and Vyxeos for AML, with Epidiolex being cannabidiol-based. The company grows its portfolio through a mix of in-house R&D and strategic acquisitions that broaden its specialty-drug lineup and global reach. Its goal is to expand approved treatments and the pipeline to help patients with limited options by building a diversified, specialty-focused portfolio.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Dublin, Ireland

Founded

2003

Get referred to Jazz Pharmaceuticals

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Second-quarter 2026 revenue hit $1.21 billion, and guidance rose to $4.75 billion.
  • Zepzelca grew 60% in Q1 2026 on first-line maintenance adoption.
  • Zanidatamab gained FDA Priority Review, positioning Jazz for a near-term oncology launch.

What critics are saying

  • Granules settlement allows a Xywav generic under certain conditions after March 2026.
  • Jazz still carries $4.35 billion debt, with $1.0 billion 2030 notes now exchangeable.
  • Zanidatamab faces an August 25, 2026 PDUFA; rejection cripples launch expectations.

What makes Jazz Pharmaceuticals unique

  • Xywav dominates narcolepsy and idiopathic hypersomnia through low-sodium oxybate differentiation.
  • Jazz owns scarce neurology and oncology assets, including Epidiolex, Zepzelca, and Ziihera.
  • Actio acquisition on August 10, 2026 extends its rare-epilepsy precision medicine franchise.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Retirement Plan

Paid Vacation

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

1%

2 year growth

0%
Yahoo Finance
Aug 11th, 2026
Jazz Pharmaceuticals Q2 revenue beats estimates at $1.21B, ups guidance to $4.68B

Jazz Pharmaceuticals reported a strong second quarter with revenue of $1.21 billion, beating analyst estimates of $1.12 billion and representing 15.5% year-on-year growth. The company raised its full-year revenue guidance to $4.68 billion from $4.38 billion. CEO Renée Galá attributed the performance to strong demand for flagship products like Xywav and Epidiolex, alongside accelerating uptake of new oncology therapies. Operating margin improved to 20.5%, up from negative 65.6% in the prior year quarter. However, adjusted earnings per share of $5.71 missed analyst expectations of $6.18. During the earnings call, analysts focused on Epidiolex's growth drivers, Xywav's sustainability amid potential generic competition, and zanidatamab's upcoming approval prospects.

Yahoo Finance
Aug 11th, 2026
Jazz Pharma raises 2026 guidance on record Q2 revenue of $1.2B, up 16%

Jazz Pharmaceuticals reported record second quarter revenue of $1.2 billion, representing 16% year-over-year growth. The company raised its full-year revenue guidance based on strong first-half performance. Chief executive officer Renée Galá attributed the results to execution across the company's diversified portfolio and sustained demand for its commercial products. The company is preparing to launch zanidatamab, with a PDUFA date of 25 August for treatment of first-line HER2-positive metastatic gastroesophageal adenocarcinoma. The earnings call included updates from senior leadership, including chief commercial officer Samantha Pearce, global head of research and development Robert Iannone, and chief financial officer Philip Johnson. Jazz Pharmaceuticals highlighted progress on its long-term value creation priorities whilst maintaining focus on current commercial operations.

Yahoo Finance
Aug 10th, 2026
Jazz Pharmaceuticals to acquire Actio Biosciences for $820M upfront, adding KCNT1+ epilepsy therapy

Jazz Pharmaceuticals has agreed to acquire Actio Biosciences for $820 million upfront and up to $500 million in contingent payments. The deal adds ABS-1230, a clinical-stage precision therapy for KCNT1+ epilepsy, to Jazz's rare epilepsy portfolio. KCNT1+ epilepsy is a rare genetic condition affecting approximately 2,500 patients in the United States. Patients typically experience dozens to hundreds of seizures daily that resist standard medications. Around 80% of cases begin in infancy, with many children unable to reach basic developmental milestones. There are currently no FDA-approved therapies for KCNT1+ epilepsy. ABS-1230 recently showed meaningful seizure reductions in an early clinical trial. The ongoing Phase 1b/2a KYRON trial is designed as the registrational study supporting US new drug application submission.

Yahoo Finance
Aug 5th, 2026
Jazz Pharmaceuticals hits $1.2B quarterly revenue, raises full-year guidance to $4.75B on oncology surge

Jazz Pharmaceuticals reported record quarterly revenue of $1.2 billion for Q2 2026, marking a 16% year-over-year increase driven by double-digit growth across all key promoted brands. The oncology portfolio grew 32% year-over-year, supported by rapid adoption of Zepzelca in first-line maintenance and the successful launch of Modeyso. Xywav demonstrated 13% revenue growth as its low-sodium profile continues to differentiate it from high-sodium generics. The company raised its full-year revenue guidance to $4.60 billion–$4.75 billion. Jazz anticipates the 25 August PDUFA date for zanidatamab in first-line HER2-positive gastric cancers, with commercial teams prepared for immediate launch. The company is leveraging its biliary tract cancer infrastructure to support the zanidatamab rollout. Non-GAAP adjusted gross margin declined slightly due to higher sales mix of royalty-bearing products.

Yahoo Finance
Jun 23rd, 2026
Jazz Pharmaceuticals' lung cancer drug fails trial but investors spared as focus shifts to first-line treatment

Jazz Pharmaceuticals' phase 3 trial evaluating Zepzelca in second-line small-cell lung cancer failed to meet its primary endpoint of overall survival. However, the setback's impact may be limited as Zepzelca's commercial focus has already shifted. In 2025, the FDA granted full approval to Zepzelca combined with Roche's Tecentriq as a first-line maintenance treatment for extensive-stage small-cell lung cancer. That approval demonstrated a 46% reduction in disease progression risk and a 27% reduction in death risk compared with Tecentriq alone. Zepzelca sales increased 60% year over year to approximately $101 million in Q1 2026, driven by first-line maintenance adoption. The drug contributed only 7% of Jazz's total 2025 revenue of $4.3 billion, with neurological medications Xywav and Epidiolex generating significantly larger sales.